A Clinical Trial of Entolimod a TLR-5 Adjuvant for Vaccines Using Diphtheria or Tetanus as Carrier Proteins

Anti-drug vaccines previously failed clinical trials because they did not provide a sufficient titer or duration of antibodies (AB), but new adjuvants enhance both AB titers and efficacy duration. This clinical trial assessed AB titers after a single booster of commercial tetanus-diphtheria (Td) vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosten, Thomas R., Domingo, Coreen B., Haile, Colin N., Nielsen, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611255/
https://www.ncbi.nlm.nih.gov/pubmed/36298456
http://dx.doi.org/10.3390/vaccines10101592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611255/
https://www.ncbi.nlm.nih.gov/pubmed/36298456
http://dx.doi.org/10.3390/vaccines10101592

Ejemplares similares